2C-T-7 Stats & Data
CCCSc1cc(OC)c(CCN)cc1OCOLEVEPDJOFPJTF-UHFFFAOYSA-NPharmacology
DrugBankMechanism of Action
Studies involving a bromine-substituted analogue, 2C-B (4-bromo-2,5- dimethoxyphenethylamine), have shown it to be a partial agonist for 5-HT2 (5-HT2A and 5-HT2C) serotonergic receptors and 1-adrenergic receptors. At 10-6 M, 2C-B also acted as a competitive 5-HT antagonist, but, at higher concentrations (2.8 x 10-5M), it acted as a non-competitive 5-HT antagonist. ... As 2C-T-7 is phenethylamine based, it is possible that it may have serotonergic receptor affinity similar to 2C-B (i.e. binding t
Metabolism
... it is likely that its metabolism may proceed via similar pathways as 2C-B, possibly with additional metabolic reactions.
Receptor Profile
Receptor Actions
History & Culture
1980–1991
2C-T-7 was developed around 1980 by Alexander Shulgin and Peyton Jacob III as part of Shulgin's extensive research program into substituted phenethylamines. The compound was first described in scientific literature by Myron Stolaroff by 1990, with more detailed characterization published by Shulgin and colleagues the following year. The compound was subsequently included in Shulgin's influential 1991 text PiHKAL (Phenethylamines I Have Known and Loved), where it holds a distinguished position among his self-designated "magical half-dozen"—the six phenethylamine compounds Shulgin considered most significant from his research. This group comprises mescaline, DOM, 2C-B, 2C-E, 2C-T-2, and 2C-T-7, with mescaline being the only member that Shulgin did not personally design and synthesize.
1991–2002
Following its publication in PiHKAL, 2C-T-7 remained relatively obscure through the 1990s, produced primarily in underground college laboratories and by small commercial research operations. Around the year 2000, availability expanded significantly as grey-market commercial vendors began supplying the compound, and it transitioned from an obscure research chemical to a recreational substance appearing at parties and clubs across North America and Europe. During this period, 2C-T-7 was sold openly in Dutch and Japanese smartshops as well as through online retailers. In the Netherlands, the compound briefly appeared on the market after 2C-T-2 had been prohibited, filling the resulting commercial gap before being banned in turn.
2002–present
In January 2002, Rolling Stone magazine published "The New (legal) Killer Drug," an article that brought substantial public attention to 2C-T-7. While the piece suggested the substance was legal, its status under United States law was actually ambiguous at the time due to the Federal Analogue Act. The accuracy of the Rolling Stone coverage was subsequently challenged in a detailed response published on the website disinfo.com. As of August 2007, at least three deaths had been reported in association with 2C-T-7 use. These fatalities involved either insufflated doses of 30 milligrams or greater, or occurred when the compound was combined with stimulants such as MDMA. The deaths and heightened media scrutiny contributed to rapid regulatory responses in multiple jurisdictions.
Subjective Effect Notes
cognitive: The head space of 2C-T-7 is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
Effect Profile
Curated + 257 ReportsStrong visuals, headspace, auditory effects, and body load
Strong stimulation, sensory enhancement, and euphoria with moderate empathy
Duration Timeline
BluelightCommunity Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Pattern inferred from general serotonergic psychedelic tolerance behavior; empirical decay to baseline typically takes 10–14 days. Users often report diminished effects if re-dosing within one week.
Cross-Tolerances
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
Erowid + BluelightEffects aggregated from 256 experience reports (206 Erowid + 51 Bluelight)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 72
Adverse Effects 51
Dose-Response Correlation
How effect frequency changes across dose levels
Insufflated
View data table
| Effect | Common (n=11) | Strong (n=12) | Heavy (n=23) |
|---|---|---|---|
| Visual Distortions | 90.9% | 83.3% | 82.6% |
| Nausea | 63.6% | 66.7% | 69.6% |
| Color Enhancement | 63.6% | 58.3% | 39.1% |
| Music Enhancement | 45.5% | 25.0% | 39.1% |
| Stimulation | 45.5% | 0% | 34.8% |
| Tactile Enhancement | 45.5% | 0% | 34.8% |
| Euphoria | 45.5% | 41.7% | 43.5% |
| Confusion | 18.2% | 25.0% | 43.5% |
| Anxiety | 36.4% | 16.7% | 39.1% |
| Closed-Eye Visuals | 36.4% | 0% | 0% |
| Empathy | 36.4% | 33.3% | 30.4% |
| Focus Enhancement | 18.2% | 33.3% | 8.7% |
| Auditory Effects | 0% | 25.0% | 30.4% |
| Hospital | 0% | 0% | 26.1% |
| Introspection | 18.2% | 25.0% | 17.4% |
Oral
View data table
| Effect | Light (n=14) | Common (n=16) | Strong (n=50) | Heavy (n=24) |
|---|---|---|---|---|
| Visual Distortions | 92.9% | 93.8% | 82.0% | 83.3% |
| Nausea | 57.1% | 56.2% | 58.0% | 62.5% |
| Auditory Effects | 0% | 25.0% | 24.0% | 58.3% |
| Stimulation | 57.1% | 31.2% | 48.0% | 41.7% |
| Color Enhancement | 50.0% | 56.2% | 44.0% | 54.2% |
| Empathy | 50.0% | 25.0% | 38.0% | 16.7% |
| Tactile Enhancement | 35.7% | 37.5% | 30.0% | 50.0% |
| Confusion | 28.6% | 31.2% | 32.0% | 50.0% |
| Anxiety | 21.4% | 50.0% | 36.0% | 41.7% |
| Music Enhancement | 28.6% | 37.5% | 46.0% | 37.5% |
| Closed-Eye Visuals | 35.7% | 12.5% | 22.0% | 20.8% |
| Euphoria | 35.7% | 25.0% | 34.0% | 33.3% |
| Muscle Tension | 35.7% | 31.2% | 26.0% | 29.2% |
| Focus Enhancement | 28.6% | 31.2% | 24.0% | 20.8% |
| Sedation | 21.4% | 31.2% | 28.0% | 25.0% |
Subjective Effect Ontology
Experience ReportsStructured effect tags extracted from 257 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.
Gastrointestinal
Visual
Dose–Effect Mapping
Experience ReportsHow reported effects shift across dose tiers, based on 206 experience reports.
| Effect | Common (n=11) | Strong (n=12) | Heavy (n=23) | |
|---|---|---|---|---|
| visual distortions | → | |||
| nausea | → | |||
| color enhancement | ↓ | |||
| music enhancement | → | |||
| stimulation | — | ↓ | ||
| tactile enhancement | — | ↓ | ||
| euphoria | → | |||
| confusion | ↑ | |||
| anxiety | → | |||
| closed-eye visuals | — | — | → | |
| empathy | ↓ | |||
| focus enhancement | ↓ | |||
| auditory effects | — | ↑ | ||
| hospital | — | — | → | |
| introspection | → | |||
| body high | — | ↓ | ||
| time distortion | — | → | ||
| pupil dilation | — | — | → | |
| open-eye visuals | — | ↓ | ||
| headache | — | — | → |
Showing top 20 of 29 effects
| Effect | Light (n=14) | Common (n=16) | Strong (n=50) | Heavy (n=24) | |
|---|---|---|---|---|---|
| visual distortions | → | ||||
| nausea | → | ||||
| auditory effects | — | ↑ | |||
| stimulation | ↓ | ||||
| color enhancement | → | ||||
| empathy | ↓ | ||||
| tactile enhancement | ↑ | ||||
| confusion | ↑ | ||||
| anxiety | ↑ | ||||
| music enhancement | ↑ | ||||
| closed-eye visuals | ↓ | ||||
| euphoria | → | ||||
| muscle tension | ↓ | ||||
| focus enhancement | ↓ | ||||
| sedation | ↑ | ||||
| memory suppression | — | ↑ | |||
| introspection | — | ↓ | |||
| dissociation | — | ↑ | |||
| open-eye visuals | — | — | ↑ | ||
| body high | → |
Showing top 20 of 33 effects
Risk Escalation
Sentiment AnalysisAverage frequency of positive vs adverse effects across dose tiers (Insufflated)
View effect breakdown
Adverse Effects
| Effect | Common (n=11) | Strong (n=12) | Heavy (n=23) | Change |
|---|---|---|---|---|
| Nausea | 9% | |||
| Confusion | +139% | |||
| Anxiety | 7% | |||
| Pupil Dilation | — | — | 0% | |
| Headache | — | — | 0% | |
| Increased Heart Rate | — | -28% | ||
| Motor Impairment | — | — | 0% | |
| Muscle Tension | — | -22% | ||
| Memory Suppression | — | — | 0% | |
| Thought Loops | — | — | 0% |
Positive Effects
| Effect | Common (n=11) | Strong (n=12) | Heavy (n=23) | Change |
|---|---|---|---|---|
| Color Enhancement | -38% | |||
| Music Enhancement | -14% | |||
| Stimulation | — | -23% | ||
| Tactile Enhancement | — | -23% | ||
| Euphoria | -4% | |||
| Empathy | -16% | |||
| Focus Enhancement | -52% | |||
| Introspection | -4% | |||
| Body High | — | -52% | ||
| Pain Relief | — | — | 0% |
Risk Escalation
Sentiment AnalysisAverage frequency of positive vs adverse effects across dose tiers (Oral)
View effect breakdown
Adverse Effects
| Effect | Light (n=14) | Common (n=16) | Strong (n=50) | Heavy (n=24) | Change |
|---|---|---|---|---|---|
| Nausea | 9% | ||||
| Confusion | +74% | ||||
| Anxiety | +94% | ||||
| Muscle Tension | -18% | ||||
| Memory Suppression | — | +16% | |||
| Sweating | — | -33% | |||
| Pupil Dilation | — | — | — | 0% | |
| Motor Impairment | — | — | -55% | ||
| Headache | — | — | — | 0% | |
| Increased Heart Rate | — | — | -52% | ||
| Jaw Clenching | — | — | -68% | ||
| Psychosis | — | — | +56% | ||
| Thought Loops | — | — | +107% |
Positive Effects
| Effect | Light (n=14) | Common (n=16) | Strong (n=50) | Heavy (n=24) | Change |
|---|---|---|---|---|---|
| Stimulation | -26% | ||||
| Color Enhancement | 8% | ||||
| Empathy | -66% | ||||
| Tactile Enhancement | +40% | ||||
| Music Enhancement | +31% | ||||
| Euphoria | -6% | ||||
| Focus Enhancement | -27% | ||||
| Introspection | — | -50% | |||
| Body High | -2% | ||||
| Creativity Enhancement | — | -33% | |||
| Pain Relief | — | — | — | 0% |
Dosage Distribution
Dose distribution from experience reports
Insufflated
Oral
Real-World Dose Distribution
62K DosesFrom 268 individual dose entries
Insufflated (n=81)
Oral (n=158)
Smoked (n=10)
Common Combinations
Most co-occurring substances in experience reports
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Insufflated
Oral
Smoked
Redose Patterns
Redosing behavior across 179 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Australia | Schedule 9 | Covered by analogue drug laws and formally added to Schedule 9 (the most restrictive category) by the National Drugs and Poisons Schedule Committee in 2005. |
| Austria | Illegal | Prohibited under the Suchtmittelgesetz (SMG). Possession, production, and sale are illegal. |
| Belgium | Controlled | Added to the list of illegal psychotropic substances on November 8, 2004. |
| Brazil | Controlled | Possession, production, and sale are illegal. Listed on Portaria SVS/MS nº 344 as of February 18, 2014. |
| Canada | Schedule III | Controlled as of October 31, 2016 as a derivative of 2,5-dimethoxyphenethylamine under the 2C-phenethylamine catch-all provision. |
| China | Category I psychotropic substance | Controlled substance as of October 2015. Illegal to sell, buy, import, export, and manufacture. |
| Denmark | Category B | Added to category B of the controlled substances list on August 23, 2003. |
| Estonia | Schedule I | Added to Schedule I in February 2011 alongside several other novel psychoactive substances. |
| Finland | Controlled | Scheduled under the government decree on substances, preparations, and plants considered to be narcotic drugs. |
| Germany | Anlage I BtMG | Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) as of July 1, 2001. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing are illegal without a license. |
| Greece | Controlled | Became a controlled substance on February 18, 2003. |
| Italy | Tabella I | Added to Tabella I (list of prohibited plants and substances) by Ministry of Health statement on January 11, 2005. |
| Latvia | Schedule I | Classified as a Schedule I controlled substance. Possession, production, and distribution are prohibited. |
| Netherlands | List I (Opiumwet) | The first country to ban 2C-T-7 after brief availability in smartshops. Following the ban on 2C-T-2, 2C-T-7 appeared on the market but was quickly prohibited under List I of the Opium Law. |
| Poland | Schedule I (I-P) | Reported as a Schedule I controlled substance. Possession, production, and distribution are prohibited. |
| Portugal | Controlled | Legislation enacted in January 2005 to control 2C-T-7 alongside 2C-I, 2C-T-2, and TMA-2. |
| Slovakia | Grade 2 | Added to Grade 2 (equivalent to Schedule II under the 1971 UN Convention on Psychotropic Substances) in October 2009. |
| Sweden | Schedule I | First classified as a health hazard under the Act on the Prohibition of Certain Goods Dangerous to Health (SFS 1999:58) as of April 1, 1999, making it illegal to sell or possess. Subsequently added to Schedule I as of March 16, 2004. |
| Switzerland | Controlled (Verzeichnis D) | Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation. |
| United Kingdom | Class A | Controlled as a Class A substance under the Misuse of Drugs Act 1971 as a result of the phenethylamine catch-all clause. In 1999, the Home Office effectively placed all compounds listed in PiHKAL into Class A. |
| United States | Schedule I | Classified as Schedule I by emergency DEA ruling on September 20, 2002. Permanently placed in Schedule I on March 18, 2004 when the DEA published a Final Rule in the Federal Register (69 FR 12794). Manufacturing, buying, possessing, or distributing without a DEA license is illegal. |
Harm Reduction
drugs.wikiEvidence-based harm-reduction points and corrections: 1) Insufflation carries disproportionate risk: at least two deaths followed nasal doses around 30–35 mg, and users frequently report burning pain, vomiting, and delirium; therefore nasal use is strongly discouraged in favor of oral titration. Source: Erowid dosage/effects pages and death summaries; EU risk communication. 2) Onset is often delayed (60–150 min, sometimes longer), which tempts premature redosing; waiting a full 3 hours before any adjustment is a practical guardrail. Source: Erowid basics/effects. 3) Likely MAO‑A involvement: sulfur‑substituted phenethylamines in this family have shown selective, reversible MAO‑A inhibition in vitro; in practice, combining 2C‑T‑7 with MAOIs (including linezolid/harmalas) or strongly serotonergic agents (MDMA, DXM, tramadol, meperidine) increases serotonin‑toxicity risk; avoid. Source: summary of Monte et al. reported on Drugs‑Forum; NCBI/StatPearls MAOI interaction guidance; Erowid deprenyl case notes. 4) Documented fatalities: at least three publicly reported deaths (two insufflated, one oral with MDMA). The prior claim of “eight deaths” is not supported by the curated sources below, so the figure is corrected to “at least three.” Source: Erowid death summaries. 5) Reagent testing: Marquis typically gives salmon orange/red with 2C‑T‑7. Use multiple reagents and beware mis-sold phenethylamines/NBOMe analogs; always test each batch. Source: Erowid Marquis chart and history notes. 6) Set, setting, sitter: high-dose reactions may include dissociation, agitation, or delirium; vomiting plus confusion increases aspiration risk; a sober sitter and calm environment reduce danger; seek emergency care for persistent chest pain, high temperature, seizures, cyanosis, or uncontrolled agitation; medical benzodiazepines are standard for severe agitation. Source: Erowid effects/overdose narratives. 7) Route cautions: IM/IV/injection has been associated with severe adverse events and is further discouraged; rectal use is less characterized—dose reductions versus oral are prudent. Source: Erowid surveys/pharmacology article. 8) Tolerance: acute tolerance emerges after one session and decays over about 10–14 days, with cross‑tolerance to serotonergic psychedelics (LSD, psilocybin). Source: TripSit general psychedelic tolerance guidance; community reports; Erowid survey patterns. 9) Street names and recognition: “T7,” “Blue Mystic,” “Beautiful,” and “Tripstasy/7‑Up” have appeared in historical markets; knowing aliases helps with test‑kit interpretation and avoiding misrepresented pills. Source: Erowid vault and East Bay Express article mirrored at Erowid. 10) Pharmacokinetics are not characterized in humans; no reliable elimination half‑life is published in the curated literature below. Duration of effects should not be conflated with half‑life. Source: Erowid basics notes “Pharmacology Summary Needed.”
References
Data Sources
Cited References
- Bluelight Trip Report - 2C-T-7 (20 mg) - New Experience (user: greenmeanies, 2010)
- Camilleri A et al. Phenethylamine Designer Drugs Review. Clin Toxicol 2013
- CDC MMWR. Deaths Associated With 2C-T-7 Use - Oklahoma & Wisconsin, 2000-2001
- Fantegrossi WE et al. Hallucinogen-like actions of 2C-T-7 in mice and rats. Psychopharmacology 2005
- Gallardo-Godoy A et al. Sulfur-Substituted α-Alkyl Phenethylamines as Selective & Reversible MAO-A Inhibitors. J Med Chem 2005
- Hartman J. An Amateur Qualitative Study of 48 2C-T-7 Bioassays
- Shulgin A; Shulgin A. PIHKAL entry #43 2C-T-7
- US-DEA Drug & Chemical Information: 2C-T-7
- Wagmann L et al. Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Drug Test Anal 2019
- Monte AP et al. Sulfur-Substituted α-Alkyl Phenethylamines as Selective & Reversible MAO-A Inhibitors. J Med Chem 2004
Drugs.wiki References
- Erowid 2C‑T‑7 Vault main
- Erowid 2C‑T‑7 Dosage
- Erowid 2C‑T‑7 Effects/Duration
- Erowid 2C‑T‑7 Basics (onset/duration, cautions)
- Erowid 2C‑T‑7 Deaths (insufflated and MDMA combo)
- Erowid ‘Sulfurous Samadhi’ Pharmacology/User surveys
- Erowid ‘Sulfurous Samadhi’ History (Blue Mystic; street names)
- Erowid Marquis reagent chart (2C‑T‑7 salmon orange/red)
- EU Drugs Agency risk note: sniffing 2C‑T‑7 increases risk of severe/lethal overdose
- EU Council Decision to control 2C‑I/2C‑T‑2/2C‑T‑7/TMA‑2
- Drugs‑Forum summary of Monte et al.: sulfur‑substituted phenethylamines as selective reversible MAO‑A inhibitors
- NCBI StatPearls: MAOIs overview and contraindications (serotonin syndrome; tyramine)
- NCBI StatPearls: Dextromethorphan (contraindicated with MAOIs)
- NCBI StatPearls: Linezolid (MAOI; serotonin syndrome risk)
- DrugBank: MAO‑A inhibition increases sumatriptan exposure
- TripSit: Psychedelic tolerance overview (1–2 weeks)